Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLU-RX-OLE
- Development stage
- Unknown
- Lead developer
- Roxall Medizin
- Administration
- Subcutaneous
01
Overview
CLU-RX-OLE is a cluster-immunotherapy allergoid developed by ROXALL Medizin GmbH for the treatment of allergic rhinitis and allergic rhinoconjunctivitis triggered by *Olea europaea* (olive tree) pollen. It consists of chemically modified pollen extracts (allergoids) adsorbed onto aluminum hydroxide. The chemical modification, typically achieved using glutaraldehyde, reduces the allergen's IgE-binding capacity, thereby lowering the risk of systemic allergic reactions while preserving the T-cell epitopes necessary for inducing immunological tolerance. The "cluster" designation refers to an accelerated updosing schedule where multiple injections are administered at short intervals, allowing patients to reach the maintenance dose more quickly than traditional subcutaneous immunotherapy (SCIT) protocols. The product aims to shift the immune response from a Th2-mediated allergic profile to a Th1/Treg-mediated tolerant profile.
- Brand names
- CLUSTOID
- Other names
- Olea europaea allergoidOlive pollen allergoid
Beyond the preview
Go deeper on CLU-RX-OLE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLU-RX-OLE.